Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Bright Minds Biosciences Announces BMB?201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
Drilling Resumes on Berrigan Zinc, Gold, Silver Property under Option from Chibougamau Independent Mines
Angkor Resources Undertakes IP Survey Over Copper/Iron Skarn Adjacent to Canada Wall Copper Porphyry Target, Andong Meas License, Cambodia
American Uranium Advances Wyoming ISR Development with Resource Growth and Confidence Upgrade at Lo Herma
